1. How to Optimize Cholesterol Management in High-Risk CV Patients

2. Agenda

3. AHA/ACC Guidelines on the Management of Blood Cholesterol

4. AHA/ACC Guideline: Lifestyle Modification for ASCVD Risk Reduction

5. Secondary Prevention in Patients Not at High ASCVD Risk

6. Secondary Prevention in Patients at Very High ASCVD Risk

7. FOURIER: Cumulative Incidence of CV Events

8. AHA/ACC Guidelines Primary Prevention of ASCVD

9. Cost-Effectiveness of PCSK9 Inhibitors

10. EAS/ESC Consensus Statement: Dyslipidemia in Very High-Risk Patients

11. Stepwise, Incremental Therapeutic Strategy for Lipid Reduction in High-Risk Patients

12. Second STEMI and Residual Risk

13. Myocardial Infarction and Life Expectancy by Sex and Ethnicity

14. 7-Year Risk of a Second MI Among 30-Day Survivors of First MI

15. Patient Case

16. Controlling Modifiable Risk Factors Is Essential in High-Risk ACS Patients

17. Addressing Residual Risk: Every MI Patient Should Be On a Statin (and Possibly Ezetimibe As Well)

18. FOURIER: Cumulative Incidence of Cardiovascular Events

19. Fourier: Results of an Exploratory Analysis in Patients with LDL-C <0.26 mM at Week 4

20. Safety Data From 5 Alirocumab Trials: No Safety Signal for Very Low LDL-C Levels

21. AHA Guidelines for Secondary ASCVD Prevention: Use of PCSK9 Inhibitors

22. Case Study in Secondary Prevention in a Patient With PAD, CAD, or Polyarterial Disease

23. Case Presentation: Patient Characteristics

24. How Should Therapy Be Advanced for This Patient?

25. Presence of Residual CV Risk in Large Prospective Studies of Optimal Statin Therapy

26. The TIMI Risk Score for Secondary Prevention

27. What Types of Events Is This Patient at Risk For?

28. How Should the Patient With Multiple Risk Factors Be Managed?

29. FOURIER: Cumulative Incidence of CV Events

30. Older Patients and Optimal LDL-C Reduction Therapy

31. Are There LDL-C Levels That Are Too Low?

32. Summary

33. Real Life Data With PCSK9 Inhibitors

34. Introduction/Overview

35. Majority of Very High-Risk Patients Not at LDL-C Level Target, < 70 mg/dL

36. EAS/ESC Consensus Statement: Dyslipidemia in Very High-Risk Patients

37. LDL-C Reduction With PCSK9 Inhibitors: Real-World Data From a Regional Lipid Clinic

38. LDL-C Reduction From Baseline With PCSK9 Inhibitors at Various Doses

39. Observational Cohort Study: CV History at Baseline (N = 1186)

40. Median (Q1, Q3) LDL-C Reduction Following Evolocumab Initiation

41. Adverse Drug Reactions: Observational Cohort Study

42. Summary and Conclusions

43. Abbreviations

44. Abbreviations (cont)

45. Abbreviations (cont)